Basic Information
Myfenax
Regulatory Information
EMEA/H/C/000884
Authorised
February 21, 2008
December 13, 2007
28
April 10, 2024
Company Information
the netherlands
Swensweg 5 2031GA Haarlem
Teva Pharma B.V.
Drug Classification
Generic Medicine
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Myfenax is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Myfenax. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Myfenax.